Vanda Pharmaceuticals Inc
$ 6.03
-3.52%
05 Jun - close price
- Market Cap 362,617,000 USD
- Current Price $ 6.03
- High / Low $ 6.29 / 6.02
- Stock P/E N/A
- Book Value 5.54
- EPS -4.06
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.60 %
- 52 Week High 9.94
- 52 Week Low 4.14
About
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
Analyst Target Price
$14.90
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-11 | 2025-10-29 | 2025-07-31 | 2025-05-07 | 2025-02-13 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-02-07 | 2023-11-08 | 2023-07-27 |
| Reported EPS | -0.82 | -2.39 | -0.38 | -0.46 | -0.5 | -0.08 | -0.09 | -0.08 | -0.07 | -0.04 | 0.0024 | 0.03 |
| Estimated EPS | -0.69 | -1.32 | -0.45 | -0.36 | -0.6 | -0.11 | -0.16 | -0.21 | 0.05 | -0.09 | -0.04 | -0.13 |
| Surprise | -0.13 | -1.07 | 0.07 | -0.1 | 0.1 | 0.03 | 0.07 | 0.13 | -0.12 | 0.05 | 0.0424 | 0.16 |
| Surprise Percentage | -18.8406% | -81.0606% | 15.5556% | -27.7778% | 16.6667% | 27.2727% | 43.75% | 61.9048% | -240% | 55.5556% | 106% | 123.0769% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.5 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VNDA
2026-06-06 14:09:25
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has released the results of its 2026 annual shareholder meeting, which included the election of three Class II directors, the ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of executive compensation, and an amendment to increase authorized shares under its 2016 Incentive Plan. Investors should closely monitor the implications of these results, particularly the potential for share dilution from the approved equity plan amendment and the notable votes against directors. The high shareholder participation rate highlights the importance of these decisions for VNDA's future governance and financial outlook.
2026-06-05 20:41:08
Vanda Pharmaceuticals Inc. announced the results of its 2026 annual stockholder meeting where shareholders approved the election of three Class II directors, ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approved an amendment to the 2016 Equity Incentive Plan to increase shares authorized for issuance. Additionally, stockholders gave advisory, non-binding approval for the compensation of the company’s named executive officers. A quorum was established with approximately 80.7% of eligible common shares represented at the meeting.
2026-05-29 17:39:03
Vanda Pharmaceuticals Inc. reported a challenging Q1 2026, missing EPS forecasts with a loss of $0.82 against an expected $0.69, and revenue fell short at $51.7 million. The stock subsequently dropped by 13.53% in after-hours trading due to investor concerns over the miss and cautious outlook. Despite strong year-over-year Fanapt sales, HETLIOZ faced pressure from generic competition, while the new product NEREUS is expected to contribute positively later in the year.
2026-05-27 14:10:14
Vanda Pharmaceuticals Inc. has received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for its drug imsidolimab, intended for the treatment of generalized pustular psoriasis. This designation grants incentives like R&D subsidies and potential 10-year market exclusivity. Despite this positive development, the company recently reported first-quarter fiscal year 2026 financial results that missed analyst expectations, with an EPS loss of $0.82 and revenue of $51.7 million, raising investor concerns.
2026-05-27 11:10:14
Vanda Pharmaceuticals has received Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare for imsidolimab, a monoclonal antibody for treating generalized pustular psoriasis (GPP). This designation provides development incentives and potential market exclusivity in Japan, where GPP affects approximately 2,200 people. Imsidolimab targets IL-36 receptor signaling, a pathway often dysregulated in GPP patients, especially within the Japanese population.
2026-05-27 11:10:14
Vanda Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare granted orphan drug designation to imsidolimab for treating generalized pustular psoriasis (GPP). This status provides significant incentives, including R&D subsidies and potential market exclusivity for up to 10 years in Japan, following similar recognition in the United States. The designation addresses a high unmet medical need for approximately 2,200 GPP patients in Japan, reinforcing imsidolimab's global potential.
